z-logo
open-access-imgOpen Access
Comparison of Atypical β3-Adrenoceptor Agonists With Their Respective Metabolic Activities in Rat White Adipocytes
Author(s) -
Yasuhito Ohsaka,
Takeshi Murakami,
Toshihide Yoshida,
Yukiko Tokumitsu
Publication year - 1998
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.77.41
Subject(s) - lipolysis , medicine , endocrinology , adenylyl cyclase , agonist , chemistry , thermogenesis , blot , white adipose tissue , adipocyte , receptor , adipose tissue , biology , biochemistry , gene
The metabolic activities of four types of beta3-adrenoceptor (AR) agonists, BRL35135A, BRL28410, ICI215001 and CL316243, were compared with those of other beta1- and beta2-AR agonists in rat white adipocytes. All the beta3-AR agonists caused cAMP formation, free fatty acid release and 2-deoxyglucose uptake; the maximum activity levels were similar except for ICI215001, which was lower. However, the magnitude of potency and selectivity of these agonists differed. The most potent and selective beta3-agonist was CL316243. Metabolic activities and Northern blotting showed that there were three beta-AR subtypes that were coupled to adenylyl cyclase and contributed to the induction of lipolysis and glucose uptake. The rank order of the amounts of beta-AR subtypes was beta3 >>beta1> beta2. However, the physiological functions of beta-AR subtypes were essentially similar in rat white adipocytes. On the other hand, cAMP accumulation and Northern blotting showed that human adipocytes predominantly contained beta2-AR, with far lower levels of beta1- and beta3-ARs. These findings suggested that the beta3-AR plays an important role in energy metabolism and thermogenesis in which cross talk exists between beta1- and beta3-ARs in rat adipocytes, while beta2-AR is the most important for the lipolysis regulation in human subcutaneous adipocytes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here